000282367 001__ 282367
000282367 005__ 20240229155040.0
000282367 0247_ $$2doi$$a10.1111/joim.13709
000282367 0247_ $$2pmid$$apmid:37641393
000282367 0247_ $$2ISSN$$a0001-6101
000282367 0247_ $$2ISSN$$a0954-6820
000282367 0247_ $$2ISSN$$a1365-2796
000282367 0247_ $$2altmetric$$aaltmetric:153429410
000282367 037__ $$aDKFZ-2023-01749
000282367 041__ $$aEnglish
000282367 082__ $$a610
000282367 1001_ $$aEdsjö, Anders$$b0
000282367 245__ $$aPrecision cancer medicine: Concepts, current practice, and future developments.
000282367 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2023
000282367 3367_ $$2DRIVER$$aarticle
000282367 3367_ $$2DataCite$$aOutput Types/Journal article
000282367 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694698812_9620$$xReview Article
000282367 3367_ $$2BibTeX$$aARTICLE
000282367 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282367 3367_ $$00$$2EndNote$$aJournal Article
000282367 500__ $$a2023 Oct;294(4):455-481
000282367 520__ $$aPrecision cancer medicine is a multidisciplinary team effort that requires involvement and commitment of many stakeholders including the society at large. Building on the success of significant advances in precision therapy for oncological patients over the last two decades, future developments will be significantly shaped by improvements in scalable molecular diagnostics in which increasingly complex multilayered datasets require transformation into clinically useful information guiding patient management at fast turnaround times. Adaptive profiling strategies involving tissue- and liquid-based testing that account for the immense plasticity of cancer during the patient's journey and also include early detection approaches are already finding their way into clinical routine and will become paramount. A second major driver is the development of smart clinical trials and trial concepts which, complemented by real-world evidence, rapidly broaden the spectrum of therapeutic options. Tight coordination with regulatory agencies and health technology assessment bodies is crucial in this context. Multicentric networks operating nationally and internationally are key in implementing precision oncology in clinical practice and support developing and improving the ecosystem and framework needed to turn invocation into benefits for patients. The review provides an overview of the diagnostic tools, innovative clinical studies, and collaborative efforts needed to realize precision cancer medicine.
000282367 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000282367 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282367 650_7 $$2Other$$aclinical trials
000282367 650_7 $$2Other$$amolecular diagnostics
000282367 650_7 $$2Other$$apersonalized oncology
000282367 650_7 $$2Other$$aprecision cancer medicine
000282367 650_7 $$2Other$$aprecision medicine networks
000282367 7001_ $$aHolmquist, Louise$$b1
000282367 7001_ $$aGeoerger, Birgit$$b2
000282367 7001_ $$aNowak, Frédérique$$b3
000282367 7001_ $$aGomon, Georgy$$b4
000282367 7001_ $$aAlix-Panabières, Catherine$$b5
000282367 7001_ $$aPloeger, Carolin$$b6
000282367 7001_ $$aLassen, Ulrik$$b7
000282367 7001_ $$aLe Tourneau, Christophe$$b8
000282367 7001_ $$aLehtiö, Janne$$b9
000282367 7001_ $$aOtt, Patrick A$$b10
000282367 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b11$$udkfz
000282367 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b12$$udkfz
000282367 7001_ $$aVoest, Emile$$b13
000282367 7001_ $$0P:(DE-HGF)0$$aKlauschen, Frederick$$b14
000282367 7001_ $$aDienstmann, Rodrigo$$b15
000282367 7001_ $$aAlshibany, Aisha$$b16
000282367 7001_ $$aSiu, Lillian L$$b17
000282367 7001_ $$00000-0003-1001-103X$$aStenzinger, Albrecht$$b18
000282367 773__ $$0PERI:(DE-600)2006883-9$$a10.1111/joim.13709$$gp. joim.13709$$n4$$p455-481$$tJournal of internal medicine$$v294$$x0001-6101$$y2023
000282367 909CO $$ooai:inrepo02.dkfz.de:282367$$pVDB
000282367 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000282367 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000282367 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000282367 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000282367 9141_ $$y2023
000282367 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-08$$wger
000282367 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000282367 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000282367 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000282367 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ INTERN MED : 2022$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-22
000282367 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ INTERN MED : 2022$$d2023-08-22
000282367 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000282367 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x1
000282367 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000282367 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x3
000282367 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x4
000282367 980__ $$ajournal
000282367 980__ $$aVDB
000282367 980__ $$aI:(DE-He78)B300-20160331
000282367 980__ $$aI:(DE-He78)B340-20160331
000282367 980__ $$aI:(DE-He78)HD01-20160331
000282367 980__ $$aI:(DE-He78)BE01-20160331
000282367 980__ $$aI:(DE-He78)MU01-20160331
000282367 980__ $$aUNRESTRICTED